Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Jazz Pharmaceuticals (JAZZ) · oqro.io/stocks/JAZZ · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Jazz Pharmaceuticals insider trading
Have Jazz Pharmaceuticals insiders bought shares recently?
No open-market purchase by an insider of Jazz Pharmaceuticals was filed in the last 90 days. The latest on record was on May 13, 2025.
How often do Jazz Pharmaceuticals insiders buy and sell shares?
Since 2007, Jazz Pharmaceuticals insiders reported 73 open-market purchases and 977 sales on Forms 4 and 5, with purchases in 10 different years, most recently 2025.
Who is selling Jazz Pharmaceuticals stock?
In the last 90 days, 5 insiders of Jazz Pharmaceuticals (JAZZ) reported 19 open-market sales worth $41.4M in total on SEC Form 4. The largest seller by value was Bruce C Cozadd, with $20.4M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade JAZZ?
No trade in Jazz Pharmaceuticals (JAZZ) was disclosed by a member of Congress in the last 12 months.
When does Jazz Pharmaceuticals report its next results?
Jazz Pharmaceuticals's next results are expected on Feb 22, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+31.0% (+$54.52) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $175.74 on Nov 20, 2025 to $230.26 on Nov 20, 2026 (+31.0%). Disclosed in this range: 26 insider trades, 33 pre-arranged insider sales, 0 Congress trades, and 27 13F position changes for 3 quarters ending in it.
$140$160$180$200$260$280$230.26
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 59 trades in this range as a list
Bruce C Cozadd, Director · 4 pre-arranged insider sales, about $16.2Mtraded Nov 6, 2026, filed Nov 10, 2026
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceuticals company based in Dublin, Ireland.
Last 12 months
+31.0%
S&P 500 +5.7% over the same dates
Market value
$14.8B
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 5.8M shares sold short (9.0% of shares outstanding), −1.1% vs the previous count, 7.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Latest results: quarter ending Sep 30, 2026
Revenue
$1.24B
+10.4% vs the same quarter a year earlier
Free cash flow, last 12 months
$1.62B
This quarter $490M, a year earlier $460M
Net debt
$3.53B
Debt $5.57B, cash $2.04B, at Sep 30, 2026
Net income, last 12 months
$206M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 2, 2026.
Since Nov 19, 2025, JAZZ is up 30.8% and the index fund is up 4.1%: 27 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much JAZZ moves
A usual day
±1.0%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
3.5%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−5.4%Jan 8, 2026
Largest one-day rise
+13.2%Feb 25, 2026
Deepest fall of the year
−21.6%From the close of Aug 4, 2026 to Oct 28, 2026.
Days of 5% or more
5Out of 252 sessions, in either direction.
Beta 0.8(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Insider buying and selling since 2007
Insiders of Jazz Pharmaceuticals reported 73 open-market purchases and 977 sales since 2007; purchases in 10 different years, most recently 2025.
Year
Bought
Sold
2026
—
$65.9M51×51 trades
2025
$9.99M4×4 trades
$27.6M37×37 trades
2024
$1.44M1×1 trade
$1.97M10×10 trades
2023
—
$5.64M33×33 trades
2022
—
$30.8M99×99 trades
2021
—
$11.8M37×37 trades
2020
$5.55M5×5 trades
$9.67M45×45 trades
2019
—
$6.35M25×25 trades
2018
$7.23M4×4 trades
$15.8M69×69 trades
2017
—
$13.8M53×53 trades
2016
$478K7×7 trades
$18.3M65×65 trades
2015
—
$60.6M179×179 trades
2014
—
$242M147×147 trades
2013
—
$569M62×62 trades
2012
—
$561M30×30 trades
2011
$112K1×1 trade
$5.2M4×4 trades
2010
$7.58M6×6 trades
$3.46M21×21 trades
2009
$1.15M6×6 trades
$74K10×10 trades
2008
$865K21×21 trades
—
2007
$474K18×18 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the public record for Jazz Pharmaceuticals over the 12 months to Nov 21, 2026: 13 clinical trials.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Late-stage clinical trials
7 active phase 3 trials and 6 active phase 2 trials led by this company, mostly in gastric neoplasms, breast cancer, narcolepsy. The ones with the nearest registered primary completion date still ahead:
1 trial has a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Last 30 days
Written by software from the filings listed below · Nov 21, 2026
Insiders. In the 30 days to Nov 21, 2026, insiders of Jazz Pharmaceuticals filed 0 open-market purchases and 8 open-market sales (about $18.1M, in 4 filings, by 3 people). One Form 4 can list many transactions. In the 30 days before that, they filed 0 open-market purchases and 2 open-market sales (about $1.85M, in 2 filings). (Jazz Pharmaceuticals on OQRO)
Contracts, lobbying and filings. ClinicalTrials.gov shows 8 studys sponsored by the company updated in the period; the latest, "A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy" (Phase 2/3, status recruiting), was updated on Nov 12, 2026, with primary completion listed for 2028-08-01. FINRA short interest for JAZZ on the settlement date of Oct 30, 2026 was 5,798,338 shares (-1.12% on the previous report), about 7.67 days of average volume.
Company reports, price and press. Jazz Pharmaceuticals filed a Form 8-K on Nov 2, 2026 (Item 2.02) that OQRO classes as: reported its results. The press release filed with it is titled: "Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results"
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 30 days to Nov 21, 2026, insiders of Jazz Pharmaceuticals filed 0 open-market purchases and 8 open-market sales (about $18.1M, in 4 filings, by 3 people). One Form 4 can list many transactions.
In the 30 days before that, they filed 0 open-market purchases and 2 open-market sales (about $1.85M, in 2 filings).
The largest sale: Bruce C Cozadd, Director, about $6.51M, filed Nov 10, 2026.
Contracts, lobbying and filings
ClinicalTrials.gov shows 8 studys sponsored by the company updated in the period; the latest, "A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy" (Phase 2/3, status recruiting), was updated on Nov 12, 2026, with primary completion listed for 2028-08-01.
FINRA short interest for JAZZ on the settlement date of Oct 30, 2026 was 5,798,338 shares (-1.12% on the previous report), about 7.67 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: William Blair Investment Management, LLC (increased, 366,010 shares); Longaeva Partners L.P. (new position); the largest that shrank: IFM Investors Pty Ltd (sold out); Alyeska Investment Group, L.P. (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press
Jazz Pharmaceuticals filed a Form 8-K on Nov 2, 2026 (Item 2.02) that OQRO classes as: reported its results.
The press release filed with it is titled: "Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results"
Its announcing sentence reads: "Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2026 (3Q26)."
Jazz Pharmaceuticals filed a Form 8-K on Oct 26, 2026 (Item 2.02) that OQRO classes as: reported its results.
Press coverage listed by Finnhub: "At Jazz Pharmaceuticals, Bruce C Cozadd Chooses To Exercise Options, Resulting In $9.46M" (Benzinga, Nov 11, 2026).
Press coverage listed by Finnhub: "Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences" (Yahoo, Nov 3, 2026).
Press coverage listed by Finnhub: "JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View" (Yahoo, Nov 3, 2026).
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Jazz Pharmaceuticals filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 67 open-market sales (about $87.9M, in 35 filings, by 11 people). One Form 4 can list many transactions. In the 12 months before that, they filed 4 open-market purchases (about $9.99M, in 1 filing) and 23 open-market sales (about $5.85M, in 16 filings). (Jazz Pharmaceuticals on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 9 new or larger positions and 18 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. ClinicalTrials.gov shows 10 studys sponsored by the company updated in the period; the latest, "A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy" (Phase 2/3, status recruiting), was updated on Nov 12, 2026, with primary completion listed for 2028-08-01. FINRA short interest for JAZZ on the settlement date of Oct 30, 2026 was 5,798,338 shares (-1.12% on the previous report), about 7.67 days of average volume.
Company reports, price and press. Jazz Pharmaceuticals filed a Form 8-K on Nov 2, 2026 (Item 2.02) that OQRO classes as: reported its results. Jazz Pharmaceuticals filed a Form 8-K on Oct 9, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
Who holds it. 641 funds reported a stake in Jazz Pharmaceuticals in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (9.3% of the value reported), FMR LLC (7.2% of the value reported), VANGUARD PORTFOLIO MANAGEMENT LLC (4.7% of the value reported).
Deals. Jazz Pharmaceuticals is the buyer of Actio Biosciences, Inc., a deal of about $820M; status: completed, first on record Aug 10, 2026.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Jazz Pharmaceuticals filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 67 open-market sales (about $87.9M, in 35 filings, by 11 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 4 open-market purchases (about $9.99M, in 1 filing) and 23 open-market sales (about $5.85M, in 16 filings).
The largest sale: Bruce C Cozadd, Director, about $6.76M, filed Dec 2, 2025.
Funds and stakes
Fund 13F filings recorded in the 12 months show 9 new or larger positions and 18 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
ClinicalTrials.gov shows 10 studys sponsored by the company updated in the period; the latest, "A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy" (Phase 2/3, status recruiting), was updated on Nov 12, 2026, with primary completion listed for 2028-08-01.
FINRA short interest for JAZZ on the settlement date of Oct 30, 2026 was 5,798,338 shares (-1.12% on the previous report), about 7.67 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: William Blair Investment Management, LLC (increased, 366,010 shares); Longaeva Partners L.P. (new position); the largest that shrank: IFM Investors Pty Ltd (sold out); Alyeska Investment Group, L.P. (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press
Jazz Pharmaceuticals filed a Form 8-K on Nov 2, 2026 (Item 2.02) that OQRO classes as: reported its results.
Jazz Pharmaceuticals filed a Form 8-K on Oct 9, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
JAZZ closed at $230.26 on Nov 20, 2026, the last session on or before the end of the period.
From Oct 21, 2026 to Nov 20, 2026, the close moved from $211.97 to $230.26, a change of +8.6%.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
The company's own opening sentence of that report reads: "On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the 'Company' ), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the..."
Jazz Pharmaceuticals filed a Form 8-K on May 29, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the 'Company') 2026 annual meeting of shareholders, has informed the board of directors (the 'Board') that she will not sta..."
Press coverage listed by Finnhub: "At Jazz Pharmaceuticals, Bruce C Cozadd Chooses To Exercise Options, Resulting In $9.46M" (Benzinga, Nov 11, 2026).
Press coverage listed by Finnhub: "Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences" (Yahoo, Nov 3, 2026).
Press coverage listed by Finnhub: "JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View" (Yahoo, Nov 3, 2026).
JAZZ closed at $247.77 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $208.43 to $247.77, a change of +18.9%.
Who holds it
641 funds reported a stake in Jazz Pharmaceuticals in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (9.3% of the value reported), FMR LLC (7.2% of the value reported), VANGUARD PORTFOLIO MANAGEMENT LLC (4.7% of the value reported).
Deals
Jazz Pharmaceuticals is the buyer of Actio Biosciences, Inc., a deal of about $820M; status: completed, first on record Aug 10, 2026.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 24, 2026. Read the filing
By region
United States$3.83B90%
+4.7% on the year before ($3.66B)
Europe$341M8.0%
+9.1% on the year before ($313M)
Other$94.9M2.2%
−1.3% on the year before ($96.1M)
Total revenue$4.27B+4.9%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 18,000 words.
From “Overview”, in the company's words
Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease – often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering R&D advancements across our robust pipeline of innovative therapeutics.
What the section covers (40 headings)
Overview
Rare Sleep Disorders
Rare Epilepsies
Rare Oncology
Other Rare Disease
Research and Development Progress
2025 Highlights and Recent Developments
Regulatory Submissions, Approvals and Commercial Launches
Research & Development
Challenges, Risks and Trends Related to Our Business
Results of Operations
Revenues
Cost of Product Sales
Selling, General and Administrative Expenses
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
3 certified in FY2026 Q3, vs 7 a year earlier. 3 positions in total, median offered wage $170K a year.
Associate Director - Statistical Programming · 1Director, DEC Global Infrastructure · 1Senior Clinical Safety Lead · 1
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
When insiders usually buy
Last results
Nov 2, 2026
Within the 30 days after it, until Dec 2, 2026
Next results, expected
Feb 22, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
100%
14 of 14 insider purchases since 2017 came within 30 days after a results announcement
From Jazz Pharmaceuticals's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Jazz Pharmaceuticals's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Off-exchange trading: 50.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (33.0% on ATS, 17.3% with other brokers), close to its 26-week average of 51.9%. Weeks of Oct 5 to Oct 30, 2026.
Week of May 4ATSOther off-exchangeFull height = all shares tradedWeek of Oct 26
Largest ATS: UBS ATS (12.9%), SIGMA X2 (11.8%), INTELLIGENT CROSS LLC (11.5%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Risk factors in the annual report
Latest annual report filed Feb 24, 2026, compared with the one filed Feb 26, 2025. Read the filing
New risk factors in the latest annual report (3 headings)
We may not realize the anticipated benefits from our acquisition of Chimerix.
Our adoption of AI technologies introduces new risks and uncertainties.
Disruptions at FDA, the SEC and other government agencies and regulatory authorities including due to a reduction in such agencies’ workforces, inadequate funding or the current and potential future government shutdowns, could prevent those agencies from performing normal functions on which our business relies, which could negatively impact our business.
Legal proceedings (Item 3)
The information required to be set forth under this Item 3 is incorporated by reference to Note 13, Commitments and Contingencies—Legal Proceedings of the Notes to Consolidated Financial Statements, included in Part IV of this Annual Report on Form 10‑K.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.